Copy to clipboard 
Vericel reported 2Q25 orthopedic sales of $53.5 million, up 21.1% compared to the second quarter of 2024. For the first half of 2025, the company generated $99.8 million in orthopedic sales, up 18.3% compared to the prior period.
MACI generated record second quarter revenue and generated the second-highest number of biopsies since launch, a leading indicator of future implants. Vericel trained 600 surgeons on the use of MACI Arthro thus far, and is poised to grow significantly in new sub-segments.
“While the treatment of patella defects remains the key driver for overall MACI growth, the treatment of small femoral condyle defects, which are the defects that MACI Arthro instruments are designed to treat increased 40% in the second quarter over the prior year,” said Vericel CEO Nick Colangelo. “This is a strong indicator that this segment, which represents approximately 1/3 of the over $3 billion addressable market for MACI, has the potential to become MACI’s highest volume growth segment over time with the MACI Arthro delivery option.”
MACI Arthro is also making inroads into the trochlea defect segment, which has accounted for 20% of MACI Arthro implants to date. Additionally, Vericel generated over 100 biopsies from arthroscopic-only surgeons, a positive indicator for growing utilization from a surgeon population that previously did not use Vericel products.
Vericel reaffirmed its 2025 MACI guidance of growth in the low 20% range.
Orthopedic Sales Data
Unless otherwise noted, all orthopedic sales data is provided in USD millions. We estimate orthopedic sales and growth rates on an as-reported basis.
Orthopedic Sales by Segment
| Segment | 2Q25 | 2Q24 | $ Chg | % Chg |
|---|---|---|---|---|
| Sports Medicine | $53.5 | $44.1 | $9.3 | 21.1% |
| Segment | 1H25 | 1H24 | $ Chg | % Chg |
|---|---|---|---|---|
| Sports Medicine | $99.8 | $84.3 | $15.4 | 18.3% |
Company Earnings
| Amt | % of Sales | |
|---|---|---|
| Sales | $63.2 | |
| Cost of Sales | $16.6 | 26.3% |
| General and Admin | $41.9 | 66.3% |
| R & D | $6.7 | 10.6% |
| Other | ($1.5) | (2.3%) |
| Net Earnings | ($0.6) | (0.9%) |
Vericel reported 2Q25 orthopedic sales of $53.5 million, up 21.1% compared to the second quarter of 2024. For the first half of 2025, the company generated $99.8 million in orthopedic sales, up 18.3% compared to the prior period.
MACI generated record second quarter revenue and generated the second-highest number of biopsies since launch,...
Vericel reported 2Q25 orthopedic sales of $53.5 million, up 21.1% compared to the second quarter of 2024. For the first half of 2025, the company generated $99.8 million in orthopedic sales, up 18.3% compared to the prior period.
MACI generated record second quarter revenue and generated the second-highest number of biopsies since launch, a leading indicator of future implants. Vericel trained 600 surgeons on the use of MACI Arthro thus far, and is poised to grow significantly in new sub-segments.
“While the treatment of patella defects remains the key driver for overall MACI growth, the treatment of small femoral condyle defects, which are the defects that MACI Arthro instruments are designed to treat increased 40% in the second quarter over the prior year,” said Vericel CEO Nick Colangelo. “This is a strong indicator that this segment, which represents approximately 1/3 of the over $3 billion addressable market for MACI, has the potential to become MACI’s highest volume growth segment over time with the MACI Arthro delivery option.”
MACI Arthro is also making inroads into the trochlea defect segment, which has accounted for 20% of MACI Arthro implants to date. Additionally, Vericel generated over 100 biopsies from arthroscopic-only surgeons, a positive indicator for growing utilization from a surgeon population that previously did not use Vericel products.
Vericel reaffirmed its 2025 MACI guidance of growth in the low 20% range.
Orthopedic Sales Data
Unless otherwise noted, all orthopedic sales data is provided in USD millions. We estimate orthopedic sales and growth rates on an as-reported basis.
Orthopedic Sales by Segment
| Segment | 2Q25 | 2Q24 | $ Chg | % Chg |
|---|---|---|---|---|
| Sports Medicine | $53.5 | $44.1 | $9.3 | 21.1% |
| Segment | 1H25 | 1H24 | $ Chg | % Chg |
|---|---|---|---|---|
| Sports Medicine | $99.8 | $84.3 | $15.4 | 18.3% |
Company Earnings
| Amt | % of Sales | |
|---|---|---|
| Sales | $63.2 | |
| Cost of Sales | $16.6 | 26.3% |
| General and Admin | $41.9 | 66.3% |
| R & D | $6.7 | 10.6% |
| Other | ($1.5) | (2.3%) |
| Net Earnings | ($0.6) | (0.9%) |
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
ME
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
